Logo

BMS’ Abecma (idecabtagene vicleucel) Receives MHLW Approval for the Treatment of Multiple Myeloma

Share this
BMS’ Abecma (idecabtagene vicleucel) Receives MHLW Approval for the Treatment of Multiple Myeloma

BMS’ Abecma (idecabtagene vicleucel) Receives MHLW Approval for the Treatment of Multiple Myeloma

Shots:

  • The approval is based on the P-II (BB2121-MM-001) study & the P-I (CRB-401) dose-expansion & escalation cohort to evaluate Abecma in 149 & 67 patients with r/r MM who have received 3 prior therapies including an immunomodulatory agent, a proteasome inhibitor & anti-CD38 Ab
  • In the P-II trial, the therapy showed ORR (73.4%) in 128 non-Japanese patients at a target dose of 150, 300, or 450 x 106 & ORR (88.9%) in 9 Japanese patients at the target dose of 450 x 106. In the P-I trial, ORR (74.2%) in the 62 patients & 84.2% in the 38 patients (target dose of 450 x 106)
  • Abecma is a BCMA-directed CAR T cell immunotherapy & 1st CAR T cell therapy approved for r/r MM in Japan

Ref: BMS | Image: BMS

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions